연구성과로 돌아가기

2025 연구성과별 연구자 정보 (318 / 1187)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Dual-controlled piezoelectric composite film with enhanced crystallinity and defect-free via solvent vapor treatment Park, Kwi-Il Park, KI 9 교신저자 Kyungpook Natl Univ, Innovat Semicond Educ & Res Ctr Future Mobil, 80 Daehak Ro, Daegu 41566, South Korea LKN-9445-2024 Park, Kwiil 0000-0002-9140-6641 Park, Kwi-Il kipark@knu.ac.kr;
Dual-controlled piezoelectric composite film with enhanced crystallinity and defect-free via solvent vapor treatment Park, Kwi-Il Park, KI 9 교신저자 Kyungpook Natl Univ, Res Inst Automot Parts & Mat, 80 Daehak Ro, Daegu 41566, South Korea LKN-9445-2024 Park, Kwiil 0000-0002-9140-6641 Park, Kwi-Il kipark@knu.ac.kr;
Dual-Modal Sensing Skin Adaptive to Daylight, Darkness, and Ultraviolet Light for Simultaneous Full-Field Deformation Measurement and Mechanoluminescence Responses Timilsina, Suman Timilsina, S 1 Kyungpook Natl Univ, KNU Res Inst Artificial Intelligent Diag Technol M, Kyeongbuk 37224, South Korea GLT-8029-2022 Timilisina, Suman 0000-0003-3362-9369 Timilsina, Suman khl@knu.ac.kr; kssohn@sejong.ac.kr; jisikkim@knu.ac.kr;
Dual-Modal Sensing Skin Adaptive to Daylight, Darkness, and Ultraviolet Light for Simultaneous Full-Field Deformation Measurement and Mechanoluminescence Responses Jo, Cheol Woo Jo, CW 2 Kyungpook Natl Univ, Sch Adv Sci & Technol Convergence, Kyeongbuk 37224, South Korea khl@knu.ac.kr; kssohn@sejong.ac.kr; jisikkim@knu.ac.kr;
Dual-Modal Sensing Skin Adaptive to Daylight, Darkness, and Ultraviolet Light for Simultaneous Full-Field Deformation Measurement and Mechanoluminescence Responses Lee, Kwang Ho Lee, KH 3 교신저자 Kyungpook Natl Univ, Dept Automot Engn, Kyeongbuk 37224, South Korea khl@knu.ac.kr; kssohn@sejong.ac.kr; jisikkim@knu.ac.kr;
Dual-Modal Sensing Skin Adaptive to Daylight, Darkness, and Ultraviolet Light for Simultaneous Full-Field Deformation Measurement and Mechanoluminescence Responses Sohn, Kee-Sun Sohn, KS 4 교신저자 Sejong Univ, Nanotechnol & Adv Mat Engn, 209 Neungdong Ro, Seoul 143747, South Korea khl@knu.ac.kr; kssohn@sejong.ac.kr; jisikkim@knu.ac.kr;
Dual-Modal Sensing Skin Adaptive to Daylight, Darkness, and Ultraviolet Light for Simultaneous Full-Field Deformation Measurement and Mechanoluminescence Responses Kim, Ji Sik Kim, JS 5 교신저자 Kyungpook Natl Univ, Sch Nano & Adv Mat Engn, Kyeongbuk 37224, South Korea 0000-0002-1432-8176 Kim, jisik khl@knu.ac.kr; kssohn@sejong.ac.kr; jisikkim@knu.ac.kr;
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study Sangro, Bruno Sangro, B 1 교신저자 Clin Univ Navarra, Liver Unit, Pamplona 31008, Spain AFW-4106-2022 Sangro, Bruno bsangro@unav.es;
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study Sangro, Bruno Sangro, B 1 교신저자 Clin Univ Navarra, HPB Oncol Area, Pamplona 31008, Spain AFW-4106-2022 Sangro, Bruno bsangro@unav.es;
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study Sangro, Bruno Sangro, B 1 교신저자 CIBEREHD, Pamplona 31008, Spain AFW-4106-2022 Sangro, Bruno bsangro@unav.es;
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study Kudo, Masatoshi Kudo, M 2 Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan AAA-9744-2019 Kudo, Masatoshi bsangro@unav.es;
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study Erinjeri, Joseph P. Erinjeri, JP 3 Mem Sloan Kettering Canc Ctr, Intervent Radiol Serv, New York, NY USA bsangro@unav.es;
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study Qin, Shukui Qin, SK 4 Jinling Hosp, Canc Ctr Nanjing, Nanjing, Peoples R China bsangro@unav.es;
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study Ren, Zhenggang Ren, ZG 5 Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Dept Hepat Oncol, Shanghai, Peoples R China bsangro@unav.es;
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study Chan, Stephen L. Chan, SL 6 Chinese Univ Hong Kong, Prince Wales Hosp, Sir Yue kong Pao Ctr Canc, Dept Clin Oncol, Hong Kong, Peoples R China F-9149-2011 Chan, Stephen bsangro@unav.es;
페이지 이동: